PANBELA THERAPEUTICS INC (PBLA) Stock Price, Quote, News and Overview
NASDAQ:PBLA - Nasdaq - US69833W4042 - Common Stock - Currency: USD
PBLA Quote, Performance and Key Statistics
1.11
-0.12 (-9.76%)
The current stock price of PBLA is 1.11 USD. In the past month the price decreased by -7.5%. In the past year, price decreased by -99.73%.
PBLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 328.74B | ||
| AMGN | AMGEN INC | 13.88 | 154.96B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
| ARGX | ARGENX SE - ADR | 97.66 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.28 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
| NTRA | NATERA INC | N/A | 21.54B | ||
| BIIB | BIOGEN INC | 8.2 | 19.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Related stock screener links
About PBLA
Company Profile
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Company Info
PANBELA THERAPEUTICS INC
712 Vista Blvd # 305
Waconia MINNESOTA 55387 US
CEO: Jennifer K. Simpson
Employees: 6
Phone: 19524791196
PANBELA THERAPEUTICS INC / PBLA FAQ
What is the stock price of PANBELA THERAPEUTICS INC today?
The current stock price of PBLA is 1.11 USD. The price decreased by -9.76% in the last trading session.
What is the ticker symbol for PANBELA THERAPEUTICS INC stock?
The exchange symbol of PANBELA THERAPEUTICS INC is PBLA and it is listed on the Nasdaq exchange.
On which exchange is PBLA stock listed?
PBLA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PANBELA THERAPEUTICS INC stock?
8 analysts have analysed PBLA and the average price target is 418.2 USD. This implies a price increase of 37575.68% is expected in the next year compared to the current price of 1.11. Check the PANBELA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PANBELA THERAPEUTICS INC worth?
PANBELA THERAPEUTICS INC (PBLA) has a market capitalization of 1.41M USD. This makes PBLA a Nano Cap stock.
How many employees does PANBELA THERAPEUTICS INC have?
PANBELA THERAPEUTICS INC (PBLA) currently has 6 employees.
What are the support and resistance levels for PANBELA THERAPEUTICS INC (PBLA) stock?
PANBELA THERAPEUTICS INC (PBLA) has a resistance level at 1.25. Check the full technical report for a detailed analysis of PBLA support and resistance levels.
Should I buy PANBELA THERAPEUTICS INC (PBLA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PBLA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PBLA, evaluating the profitability, health, valuation and growth aspects
- PANBELA THERAPEUTICS INC (PBLA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PANBELA THERAPEUTICS INC (PBLA) Sales and EPS estimates to see what analysts future expectations are.
- PANBELA THERAPEUTICS INC (PBLA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PANBELA THERAPEUTICS INC (PBLA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PANBELA THERAPEUTICS INC (PBLA) Stock Chart to make your own analysis
- PANBELA THERAPEUTICS INC (PBLA) Latest news and press-releases to stay up to date.
Does PANBELA THERAPEUTICS INC (PBLA) stock pay dividends?
PBLA does not pay a dividend.
When does PANBELA THERAPEUTICS INC (PBLA) report earnings?
PANBELA THERAPEUTICS INC (PBLA) will report earnings on 2024-05-02, after the market close.
What is the Price/Earnings (PE) ratio of PANBELA THERAPEUTICS INC (PBLA)?
PANBELA THERAPEUTICS INC (PBLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4010.88).
What is the Short Interest ratio of PANBELA THERAPEUTICS INC (PBLA) stock?
The outstanding short interest for PANBELA THERAPEUTICS INC (PBLA) is 0.13% of its float. Check the ownership tab for more information on the PBLA short interest.
PBLA Technical Analysis
PBLA Financial Highlights
Over the last trailing twelve months PBLA reported a non-GAAP Earnings per Share(EPS) of -4010.88. The EPS decreased by -67.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PBLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PBLA. The Buy consensus is the average rating of analysts ratings from 8 analysts.